HTL0018318 + Placebo

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dementia With Lewy Bodies

Conditions

Dementia With Lewy Bodies

Trial Timeline

Jul 1, 2019 → Jan 1, 2021

NCT ID

NCT03592862

About HTL0018318 + Placebo

HTL0018318 + Placebo is a phase 2 stage product being developed by Nxera Pharma for Dementia With Lewy Bodies. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03592862. Target conditions include Dementia With Lewy Bodies.

What happened to similar drugs?

6 of 20 similar drugs in Dementia With Lewy Bodies were approved

Approved (6) Terminated (1) Active (13)

🔄[18F]NAV4694Navidea BiopharmaceuticalsPhase 3

❌AL001 + Placebo + Open label - AL001AlectorPhase 3

✅E2020 + PlaceboEisaiApproved

🔄ARICEPTEisaiPhase 3

🔄donepezil hclEisaiPhase 3

🔄Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3

✅donepezil hydrochloride (Aricept)EisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03592862	Phase 2	Withdrawn	Jul 1, 2019	Jan 1, 2021	Dementia With Lewy Bodies
NCT03456349	Phase 1	Completed	Nov 10, 2017	Jul 16, 2018	Alzheimer's Disease

Competing Products

20 competing products in Dementia With Lewy Bodies

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40